Losartan: Difference between revisions
| (5 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Antihypertensive]], [[ARB]] | *Type: [[Antihypertensive]], [[ARB]] | ||
*Dosage Forms: | *Dosage Forms: Tablet; 25mg, 50mg, 100mg | ||
*Routes of Administration: oral | *Routes of Administration: oral | ||
*Common Trade Names: Cozaar | *Common Trade Names: Cozaar | ||
| Line 8: | Line 8: | ||
===[[Hypertension]]=== | ===[[Hypertension]]=== | ||
*25-150mg PO daily | *25-150mg PO daily | ||
*Occasionally outpatient will prescribe BID dosing of losartan for potential continuous BP control (or [[lisinopril]]) | |||
**2020 large scale Kaiser study concluded no increased efficacy | |||
**There is potential for risk for AKI and hyperkalemia with lisinopril, but not losartan -- hypotension was not investigated<ref>Derington et al. Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. PLoS One. 2020 Dec 3;15(12):e0243371. doi: 10.1371/journal.pone.0243371</ref> | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 20: | Line 23: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Concomitant use with aliskiren in diabetes | *Concomitant use with [[aliskiren]] in diabetes | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Acute kidney injury | *[[Acute kidney injury]] | ||
* | *[[Rhabdomyolysis]] | ||
*Syncope | *[[Syncope]] | ||
*Stroke | *[[Stroke]] | ||
*Angioedema | *[[Angioedema]] | ||
===Common=== | ===Common=== | ||
*Backache | *[[Backache]] | ||
*Dizziness | *[[Dizziness]] | ||
*Cough, URI symptoms | *[[Cough]], [[URI]] symptoms | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 46: | Line 50: | ||
==See Also== | ==See Also== | ||
*[[Hypertension]] | *[[Hypertension]] | ||
*[[Angiotensin II receptor antagonists]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Cardiology]] | |||
Latest revision as of 16:59, 22 April 2025
Administration
- Type: Antihypertensive, ARB
- Dosage Forms: Tablet; 25mg, 50mg, 100mg
- Routes of Administration: oral
- Common Trade Names: Cozaar
Adult Dosing
Hypertension
- 25-150mg PO daily
- Occasionally outpatient will prescribe BID dosing of losartan for potential continuous BP control (or lisinopril)
- 2020 large scale Kaiser study concluded no increased efficacy
- There is potential for risk for AKI and hyperkalemia with lisinopril, but not losartan -- hypotension was not investigated[1]
Pediatric Dosing
- 0.1 to 1.4 mg/kg daily
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: starting dose 25mg daily
Contraindications
- Allergy to class/drug
- Concomitant use with aliskiren in diabetes
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 2-6 hours
- Metabolism: Hepatic;P450 CYP2C9 and CYP3A4
- Excretion: Fecal, renal
Mechanism of Action
- Reversible angiotensin II inhibitor
Comments
See Also
References
- ↑ Derington et al. Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety. PLoS One. 2020 Dec 3;15(12):e0243371. doi: 10.1371/journal.pone.0243371